Company Profile
Noctrix Health is a US-based manufacturer of wearable neuromodulation therapies, headquartered in Pleasanton, California, USA. Founded in 2018 by Shriram Raghunathan, Ph.D. and Jonathan Charlesworth, Ph.D., the company operates as an independent private entity pending acquisition by ResMed Inc., serving global restless legs syndrome (RLS) markets with prescription wearable devices.
Core Products ＆ Technologies
Wearable RLS Therapy
• Nidra (NTX100 TOMAC System): FDA-cleared, non-invasive wearable device delivering tonic motor activation to bilateral peroneal nerves for moderate-to-severe RLS
• TOMAC Technology: Proprietary sustained neuromuscular activation system designed to suppress RLS symptoms during sleep without medication
Market Position ＆ Certifications
Noctrix Health holds an emerging leadership position in the global wearable neuromodulation market, competing with Medtronic (implantable neuromodulation) and Abbott (neurostimulation). Key strengths include:
• 8 years of US engineering heritage in wearable therapeutic development
• Breakthrough recognition: FDA Breakthrough Device Designation (May 2020)
• Regulatory compliance: FDA De Novo cleared (DEN220059, April 17, 2023)
• Clinical evidence: 133-patient RESTFUL study met all 7 primary and secondary endpoints; 24-week extension showed 72.7% responder rate and 3.5-fold increase in symptom-free days
• Venture backing: $40M Series C (January 2024) led by Sectoral Asset Management with participation from ResMed, OrbiMed, and others
Corporate Timeline
2018 — Founded in Pleasanton, California, USA
2020 — Granted FDA Breakthrough Device Designation for NTX100
2021 — Enrolled first patient in the pivotal RESTFUL clinical trial
2023 — Received FDA De Novo clearance for NTX100 TOMAC System (DEN220059, April 17)
2024 — Closed $40M Series C financing (January) to support commercial launch
2026 — ResMed announced $340M acquisition agreement (April); expected close on or around June 1, 2026
Target Markets ＆ Applications
• Restless Legs Syndrome (RLS): Nidra device for moderate-to-severe primary RLS refractory to standard medications
• Neurological Sleep Disorders: Non-pharmacologic alternative to dopaminergic therapies for chronic RLS management
• Home-Use Wearable Therapy: Prescription bilateral leg bands for overnight symptom suppression and sleep quality improvement
Contact Information
Global Headquarters
Address: 6700 Koll Center Pkwy, Suite 310, Pleasanton, CA 94566, USA
Email: info@noctrixhealth.com
Parent Company (Pending Acquisition)
ResMed Inc.
Address: San Diego, California, USA
Stock: NYSE: RMD / ASX: RMD
Website: resmed.com
Investor Relations: investor.resmed.com
